Equities Analysts Issue Forecasts for Marinus Pharmaceuticals, Inc.’s Q3 2024 Earnings (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Equities research analysts at Leerink Partnrs dropped their Q3 2024 earnings per share estimates for shares of Marinus Pharmaceuticals in a research note issued on Tuesday, August 13th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will earn ($0.45) per share for the quarter, down from their previous forecast of ($0.37). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($1.87) per share. Leerink Partnrs also issued estimates for Marinus Pharmaceuticals’ Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($1.95) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at $0.15 EPS and FY2028 earnings at $0.55 EPS.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The company had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative return on equity of 518.13% and a negative net margin of 513.80%. During the same period in the prior year, the company posted ($0.61) earnings per share.

MRNS has been the subject of a number of other reports. StockNews.com upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. Truist Financial reissued a “buy” rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th. LADENBURG THALM/SH SH downgraded Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Marinus Pharmaceuticals in a research note on Wednesday. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, Marinus Pharmaceuticals currently has an average rating of “Hold” and an average price target of $12.75.

Marinus Pharmaceuticals Stock Performance

Shares of MRNS stock opened at $1.26 on Friday. The company has a market capitalization of $69.22 million, a price-to-earnings ratio of -0.48 and a beta of 1.13. The company has a debt-to-equity ratio of 5.68, a quick ratio of 2.93 and a current ratio of 3.07. Marinus Pharmaceuticals has a one year low of $1.05 and a one year high of $11.26. The company’s 50-day moving average is $1.33 and its 200 day moving average is $4.30.

Institutional Trading of Marinus Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC bought a new position in shares of Marinus Pharmaceuticals during the 4th quarter valued at approximately $134,000. Point72 DIFC Ltd purchased a new stake in shares of Marinus Pharmaceuticals in the second quarter valued at $28,000. AQR Capital Management LLC lifted its holdings in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 12,934 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Marinus Pharmaceuticals during the 1st quarter valued at about $384,000. Finally, Trexquant Investment LP purchased a new stake in Marinus Pharmaceuticals in the 4th quarter worth about $553,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.